{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T15:22:27Z","timestamp":1776784947969,"version":"3.51.2"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The clinical outcomes of drug-eluting beads transarterial chemoembolization (DEB-TACE) with doxorubicin-loaded CalliSpheres\u00ae beads for patients with unresectable or recurrent esophageal carcinoma have not been reported. The aim of this study is to study the clinical outcomes of DEB-TACE for patients with unresectable or recurrent esophageal carcinoma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective study enrolled 21 patients (15 men; mean age 68.7\u2009\u00b1\u20099.7; range 46\u201386 years) with unresectable or recurrent esophageal carcinoma received DEB-TACE between July 2017 and September 2020. Patient characteristic data, imaging findings, complications and DEB-TACE procedure were reviewed. The primary endpoints, disease control rate (DCR) and objective response rate (ORR), were calculated. The secondary endpoints were overall survival rate and progression-free survival (PFS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-two sessions of DEB-TACE were performed in 21 patients. The technical success rate was 100%; without sever adverse events or procedure-related deaths. All patients received transarterial chemotherapy infusion with raltitrexed or oxaliplatin. The median follow-up period was 3.6 months (interquartile range, IQR 1.5\u20139.4 months). ORR and DCR were 42.9 and 85.7%, 28.6 and 71.4%, 20.0 and 40.0% respectively at 1-, 3-, and 6-months after DEB-TACE. The median PFS was 6.0 months, and the 3-, 6- and 12-month PFS rates were 68.2%, 45.5 and 0.0%, respectively. The median overall survival was 9.4 months, and the 3-, 6- and 12-month overall survival rates were 75.5%, 55.0 and 13.8%, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>To our knowledge, this is the first study reports outcomes of DEB-TACE with doxorubicin-loaded CallSpheres bead treatment in the management of patients with unresectable or recurrent esophageal carcinoma. According to our results, this is a safe and feasible treatment modality that may be considered among the options for the treatment of these patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-021-01816-3","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T09:04:25Z","timestamp":1621587865000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Clinical outcomes of doxorubicin-eluting CalliSpheres\u00ae beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma"],"prefix":"10.1186","volume":"21","author":[{"given":"Yonghua","family":"Bi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaonan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzhuang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengfei","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-6427","authenticated-orcid":false,"given":"Xinwei","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,21]]},"reference":[{"issue":"4","key":"1816_CR1","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1007\/s00330-008-1216-2","volume":"19","author":"HJ Lee","year":"2009","unstructured":"Lee HJ, Shin JH, Yoon HK, Ko GY, Gwon DI, Song HY, Sung KB. Transcatheter arterial embolization in gastric cancer patients with acute bleeding. Eur Radiol. 2009;19(4):960\u20135.","journal-title":"Eur Radiol"},{"issue":"7","key":"1816_CR2","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.jvir.2017.03.017","volume":"28","author":"S Park","year":"2017","unstructured":"Park S, Shin JH, Gwon DI, Kim HJ, Sung KB, Yoon HK, Ko GY, Ko HK. Transcatheter arterial embolization for gastrointestinal bleeding associated with gastric carcinoma: prognostic factors predicting successful hemostasis and survival. J Vasc Interv Radiol. 2017;28(7):1012\u201321.","journal-title":"J Vasc Interv Radiol"},{"issue":"6","key":"1816_CR3","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jvir.2014.02.005","volume":"25","author":"T Meehan","year":"2014","unstructured":"Meehan T, Stecker MS, Kalva SP, Oklu R, Walker TG, Ganguli S. Outcomes of transcatheter arterial embolization for acute hemorrhage originating from gastric adenocarcinoma. J Vasc Interv Radiol. 2014;25(6):847\u201351.","journal-title":"J Vasc Interv Radiol"},{"issue":"12","key":"1816_CR4","first-page":"1329","volume":"25","author":"KC Kwan","year":"1997","unstructured":"Kwan KC. Oral bioavailability and first-pass effects. Drug Metab Dispos. 1997;25(12):1329\u201336.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"1816_CR5","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s00270-015-1208-y","volume":"39","author":"T de Baere","year":"2016","unstructured":"de Baere T, Arai Y, Lencioni R, Geschwind JF, Rilling W, Salem R, Matsui O, Soulen MC. Treatment of liver tumors with lipiodol TACE: technical recommendations from experts opinion. Cardiovasc Intervent Radiol. 2016;39(3):334\u201343.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"28","key":"1816_CR6","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.2217\/fon-2018-0136","volume":"14","author":"F Melchiorre","year":"2018","unstructured":"Melchiorre F, Patella F, Pescatori L, Pesapane F, Fumarola E, Biondetti P, Brambillasca P, Monaco C, Ierardi AM, Franceschelli G, et al. DEB-TACE: a standard review. Future Oncol. 2018;14(28):2969\u201384.","journal-title":"Future Oncol"},{"issue":"1","key":"1816_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12957-018-1368-8","volume":"16","author":"B Wu","year":"2018","unstructured":"Wu B, Zhou J, Ling G, Zhu D, Long Q. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study. World J Surg Oncol. 2018;16(1):69.","journal-title":"World J Surg Oncol"},{"key":"1816_CR8","doi-asserted-by":"publisher","first-page":"153303381983075","DOI":"10.1177\/1533033819830751","volume":"18","author":"H Xiang","year":"2019","unstructured":"Xiang H, Long L, Yao Y, Fang Z, Zhang Z, Zhang Y. CalliSpheres drug-eluting bead transcatheter arterial chemoembolization presents with better efficacy and equal safety compared to conventional TACE in treating patients with hepatocellular carcinoma. Technol Cancer Res Treat. 2019;18:1533033819830751.","journal-title":"Technol Cancer Res Treat"},{"issue":"1","key":"1816_CR9","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1186\/s12885-018-4566-4","volume":"18","author":"GH Zhou","year":"2018","unstructured":"Zhou GH, Han J, Sun JH, Zhang YL, Zhou TY, Nie CH, Zhu TY, Chen SQ, Wang BQ, Yu ZN, et al. Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheres(R) beads in Chinese hepatocellular carcinoma patients. BMC Cancer. 2018;18(1):644.","journal-title":"BMC Cancer"},{"issue":"9","key":"1816_CR10","first-page":"586","volume":"85","author":"BD Liu","year":"2005","unstructured":"Liu BD, Zhi XY, Xu QS. The value of postoperative arterial infusion chemotherapy in patients with T3 esophageal squamous carcinoma after radical surgery. Zhonghua Yi Xue Za Zhi. 2005;85(9):586\u20139.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"1816_CR11","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, Denlinger CS, Enzinger PC, Fanta P, Farjah F, et al. Esophageal and Esophagogastric Junction Cancers, Version 5.2020, NCCN Clinical Practice Guidelines in Oncology. https:\/\/www.nccn.org\/patients\/guidelines\/cancers.aspx. Accessed 23 Dec 1998."},{"issue":"2","key":"1816_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"key":"1816_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12957-016-0803-y","volume":"14","author":"M Aoki","year":"2016","unstructured":"Aoki M, Tokue H, Koyama Y, Tsushima Y, Oshima K. Transcatheter arterial embolization with N-butyl cyanoacrylate for arterial esophageal bleeding in esophageal cancer patients. World J Surg Oncol. 2016;14:54.","journal-title":"World J Surg Oncol"},{"issue":"12","key":"1816_CR14","first-page":"2167","volume":"40","author":"H Nagase","year":"2013","unstructured":"Nagase H, Kawasaki H, Wajima N, Nakai M, Kimura A, Nakayama Y, Hakamada K. Two cases of bleeding from locally advanced esophageal cancer successfully treated by transcatheter arterial embolization. Gan To Kagaku Ryoho. 2013;40(12):2167\u20139.","journal-title":"Gan To Kagaku Ryoho"},{"issue":"11","key":"1816_CR15","first-page":"1407","volume":"42","author":"N Kennoki","year":"2015","unstructured":"Kennoki N, Hori S, Yuki T, Sueyoshi S, Hori A. Transcatheter arterial chemoembolization with super absorbent polymer microspheres for a large lung cystic adenocarcinoma in the left pulmonary cavity. Gan To Kagaku Ryoho. 2015;42(11):1407\u201310.","journal-title":"Gan To Kagaku Ryoho"},{"issue":"12","key":"1816_CR16","first-page":"1827","volume":"42","author":"N Kennoki","year":"2015","unstructured":"Kennoki N, Hori S, Yuki T, Sueyoshi S, Hori A. Trans-arterial chemoembolization therapy for refractory advanced non-small cell lung cancer with spherical embolic material: a single case report. Gan To Kagaku Ryoho. 2015;42(12):1827\u20139.","journal-title":"Gan To Kagaku Ryoho"},{"issue":"6","key":"1816_CR17","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s00270-013-0576-4","volume":"36","author":"A Seki","year":"2013","unstructured":"Seki A, Hori S, Sueyoshi S, Hori A, Kono M, Murata S, Maeda M. Transcatheter arterial embolization with spherical embolic agent for pulmonary metastases from renal cell carcinoma. Cardiovasc Intervent Radiol. 2013;36(6):1527\u201335.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1816_CR18","doi-asserted-by":"crossref","unstructured":"Bi Y, Shi X, Ren J, Yi M, Han X, Song M. Transarterial chemoembolization with doxorubicin-loaded beads for inoperable or recurrent colorectal cancer. Abdom Radiol (NY) 2021.","DOI":"10.1007\/s00261-020-02877-w"},{"key":"1816_CR19","doi-asserted-by":"crossref","unstructured":"Bi Y, Shi X, Yi M, Han X, Ren J. Pirarubicin-loaded CalliSpheres(R) drug-eluting beads for the treatment of patients with stage III-IV lung cancer. Acta Radiol 2021:284185121994298.","DOI":"10.1177\/0284185121994298"},{"issue":"12","key":"1816_CR20","doi-asserted-by":"publisher","first-page":"e115898","DOI":"10.1371\/journal.pone.0115898","volume":"9","author":"JW Choi","year":"2014","unstructured":"Choi JW, Cho HJ, Park JH, Baek SY, Chung JW, Kim DD, Kim HC. Comparison of drug release and pharmacokinetics after transarterial chemoembolization using diverse lipiodol emulsions and drug-eluting beads. PLoS One. 2014;9(12):e115898.","journal-title":"PLoS One"},{"issue":"2","key":"1816_CR21","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1148\/radiol.2018172571","volume":"289","author":"AS Mikhail","year":"2018","unstructured":"Mikhail AS, Pritchard WF, Negussie AH, Krishnasamy VP, Amchin DB, Thompson JG, Wakim PG, Woods D, Bakhutashvili I, Esparza-Trujillo JA, et al. Mapping drug dose distribution on CT images following transarterial chemoembolization with radiopaque drug-eluting beads in a rabbit tumor model. Radiology. 2018;289(2):396\u2013404.","journal-title":"Radiology"},{"issue":"7","key":"1816_CR22","first-page":"917","volume":"40","author":"K Kunisada","year":"2013","unstructured":"Kunisada K, Ishikawa H, Takafuji J, Komuta K. A case of a 91-year-old patient with advanced squamous cell lung cancer complicated with renal dysfunction successfully treated with trans-arterial chemo-embolization. Gan To Kagaku Ryoho. 2013;40(7):917\u20139.","journal-title":"Gan To Kagaku Ryoho"},{"issue":"1","key":"1816_CR23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12876-018-0848-1","volume":"18","author":"YS Liu","year":"2018","unstructured":"Liu YS, Lin CY, Chuang MT, Tsai YS, Wang CK, Ou MC. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. BMC Gastroenterol. 2018;18(1):124.","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"1816_CR24","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S1499-3872(16)60133-9","volume":"15","author":"AH Cheung","year":"2016","unstructured":"Cheung AH, Lam CS, Tam HS, Cheung TT, Pang R, Poon RT. Nine-year experience of doxorubicin-eluting beads chemoembolization for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2016;15(5):493\u20138.","journal-title":"Hepatobiliary Pancreat Dis Int"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01816-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-021-01816-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01816-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T21:02:42Z","timestamp":1621630962000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-021-01816-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,21]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1816"],"URL":"https:\/\/doi.org\/10.1186\/s12876-021-01816-3","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,21]]},"assertion":[{"value":"7 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of The First Affiliated Hospital of Zhengzhou University. Informed consent was waived due to its retrospective nature.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consents were obtained from the patients for publication. A copy of the written consent is available for review by the Editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"231"}}